Loading, Please Wait...
TUCSON, Ariz., Aug. 16, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the appointment of Ms. Michelle Griffin to its Board of Directors.
“We are pleased to welcome Michelle to our Board,” said TJ Johnson, Chief Executive Officer of HTG. “Michelle brings deep financial and accounting expertise, in addition to her extensive executive experience, making her insights invaluable as HTG continues its growth trajectory. She will be a tremendous asset to our Board, and we look forward to her contributions.”
Ms. Griffin added, “I am excited to join this thoughtful and dynamic group. HTG’s technology is exciting and has the potential to change the practice of medicine, and I look forward to contributing to its success.”
About Michelle Griffin
Ms. Michelle Griffin is the founder of Pacific Biotechnology Consulting Group, a firm that provides consulting services to biotechnology companies and boards of directors. She currently serves as a member of the board of directors and chair of the audit committee for Acer Therapeutics, Inc (Nasdaq: ACER). She has also served on the board of directors and as audit committee chair for PhaseRx, Inc. from 2016 to 2018, OncoGenex Pharmaceuticals Inc. from 2008 to 2011, and Sonus Pharmaceuticals, Inc. from 2004 to 2008; as chair of the board of directors for Universal Cells, Inc. from 2017 until its acquisition by Astellas Pharma Inc. in 2018; as a member of the board of directors of Virginia Mason Health System and Virginia Mason Medical Center from 2014 to 2018; and as a member of the board of directors for Polynoma LLC from 2012 to 2014. Prior to founding her consultancy firm, Ms. Griffin served as executive vice president, operations and chief financial officer at OncoGenex from 2011 to 2013, and also served as acting chief executive, senior vice president and chief operating officer at Trubion Pharmaceuticals, Inc. from 2009 until its acquisition in 2010 and as its chief financial officer from 2006 to 2009; and served as senior vice president and chief financial officer of Dendreon Corp. from 2005 to 2006. Ms. Griffin began her career in the biopharmaceuticals industry in 1994 at Corixa Corp. and served as its chief financial officer from its IPO in 1997 until 2005 when Corixa was acquired by GlaxoSmithKline plc. She received a post‐graduate certificate in accounting and an MBA from Seattle University, a B.S. in statistics and marketing from George Mason University and has passed the certified public accountant exam.
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our newly appointed director and her expected benefits to us and the capabilities of our technology. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; the level and availability of first party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of first parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 525-7754
Chief Executive Officer
HTG Molecular Diagnostics
Phone: (520) 547-2827 x130